Speaker: Dr Erwan Bezard, CSO of Motac Neuroscience.
The concept of synucleopathies (Parkinson’s disease, Multiple System Atrophy, Dementia with Lewy Bodies) being actual prion-like diseases supported by the pathological aggregation (and spreading) of the ubiquitously alpha-synuclein has revolutionized the search for disease-modifying therapies.
A myriad of experimental models (and readouts) has emerged using different triggers rendering quite complex the selection of the models of choice for the translational preclinical validation of experimental therapeutics.
This presentation will emphasize how such knowledge can be used for increasing the likelihood of successful translation to the clinic of therapeutics aiming at lowering the synucleopathic burden.
About Neuroservices-Alliance & Motac Neuroscience
Neuroservices Alliance is a one-stop shop preclinical CNS CRO, providing pharmaceutical industries with functional endpoints in neuro-pharmacology.
As a member of Neuroservices-Alliance, Motac provides highly-specialised preclinical services for the pharmaceutical and biotechnology industries to support the discovery and development of therapeutics for neurological and psychiatric disorders. Motac has extensive expertise and world-class research capabilities in neurodegenerative conditions, particularly Parkinson’s disease, other movement disorders and cognitive disorders.
About Dr. Erwan Bezard
Dr. Bezard, INSERM Research Director, has authored or co-authored over 260 professional publications in the field of neurobiology, most of which are on Parkinson’s disease and related disorders. Listed in the Top 1% of the most cited neuroscientists, he is best known for his work on the compensatory mechanisms that mask the progression of Parkinson’s disease and on the pathophysiology of levodopa-induced dyskinesia.
20 min – Presentation
10 min – Live Questions & Answers
The session will be recorded and every registrant will receive a link to access it after the event